Neumora Therapeutics Inc.’s filing revealed that its Director Burow Kristina acquired Company’s shares for reported $40217.0 on Nov 14 ’23. In the deal valued at $11.98 per share,3,357 shares were bought. As a result of this transaction, Burow Kristina now holds 4,131,207 shares worth roughly $40.53 million.
Then, ARCH Venture Partners XII, LLC bought 3,357 shares, generating $40,217 in total proceeds. Upon buying the shares at $11.98, the 10% Owner now owns 4,131,207 shares.
Before that, ARCH Venture Partners XII, LLC bought 31,653 shares. Neumora Therapeutics Inc. shares valued at $371,923 were divested by the 10% Owner at a price of $11.75 per share. As a result of the transaction, ARCH Venture Partners XII, LLC now holds 4,127,850 shares, worth roughly $40.49 million.
Deutsche Bank initiated its Neumora Therapeutics Inc. [NMRA] rating to a Hold in a research note published on December 12, 2023; the price target was $13. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in early October with a ‘”an Outperform”‘ rating. Stifel began covering NMRA with “Buy” recommendation on October 10, 2023. RBC Capital Mkts started covering the stock on October 10, 2023. It rated NMRA as “an Outperform”.
Price Performance Review of NMRA
On Tuesday, Neumora Therapeutics Inc. [NASDAQ:NMRA] saw its stock jump 4.92% to $9.81. Over the last five days, the stock has gained 7.92%. Neumora Therapeutics Inc. shares have fallen nearly -42.46% since the year began. A total of 0.48 million shares were traded, compared to the trading of 0.38 million shares in the previous session.
Levels Of Support And Resistance For NMRA Stock
The 24-hour chart illustrates a support level at 9.24, which if violated will result in even more drops to 8.66. On the upside, there is a resistance level at 10.15. A further resistance level may holdings at 10.48. The Relative Strength Index (RSI) on the 14-day chart is 36.35, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.14, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 52.55%. Stochastics %K at 28.09% indicates the stock is a holding.
The most recent change occurred on October 10, 2023 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $21 price target.
